You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Boehringer Ingelheim
Moodys
AstraZeneca
McKinsey

Last Updated: July 5, 2020

DrugPatentWatch Database Preview

SEEBRI Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Seebri patents expire, and what generic alternatives are available?

Seebri is a drug marketed by Novartis and is included in one NDA. There are twelve patents protecting this drug.

This drug has three hundred and twenty-nine patent family members in forty-one countries.

The generic ingredient in SEEBRI is glycopyrrolate. There are seventeen drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the glycopyrrolate profile page.

US ANDA Litigation and Generic Entry Outlook for Seebri

A generic version of SEEBRI was approved as glycopyrrolate by AM REGENT on July 23rd, 1986.

  Start Trial

Drug patent expirations by year for SEEBRI
Drug Prices for SEEBRI

See drug prices for SEEBRI

Recent Clinical Trials for SEEBRI

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of SaskatchewanPhase 4
Sunovion Respiratory Development Inc.Phase 1

See all SEEBRI clinical trials

Pharmacology for SEEBRI
Drug ClassAnticholinergic
Mechanism of ActionCholinergic Antagonists

US Patents and Regulatory Information for SEEBRI

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis SEEBRI glycopyrrolate POWDER;INHALATION 207923-001 Oct 29, 2015 DISCN Yes No   Start Trial   Start Trial   Start Trial
Novartis SEEBRI glycopyrrolate POWDER;INHALATION 207923-001 Oct 29, 2015 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Novartis SEEBRI glycopyrrolate POWDER;INHALATION 207923-001 Oct 29, 2015 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Novartis SEEBRI glycopyrrolate POWDER;INHALATION 207923-001 Oct 29, 2015 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Novartis SEEBRI glycopyrrolate POWDER;INHALATION 207923-001 Oct 29, 2015 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Novartis SEEBRI glycopyrrolate POWDER;INHALATION 207923-001 Oct 29, 2015 DISCN Yes No   Start Trial   Start Trial   Start Trial
Novartis SEEBRI glycopyrrolate POWDER;INHALATION 207923-001 Oct 29, 2015 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for SEEBRI

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis SEEBRI glycopyrrolate POWDER;INHALATION 207923-001 Oct 29, 2015   Start Trial   Start Trial
Novartis SEEBRI glycopyrrolate POWDER;INHALATION 207923-001 Oct 29, 2015   Start Trial   Start Trial
Novartis SEEBRI glycopyrrolate POWDER;INHALATION 207923-001 Oct 29, 2015   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for SEEBRI

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1267866 493 Finland   Start Trial
1267866 132013902141564 Italy   Start Trial PRODUCT NAME: GLICOPIRRONIO BROMURO(SEEBRI BREEZHALER); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/12/788/001-006, 20120928
2435025 2019C/532 Belgium   Start Trial PRODUCT NAME: UNE COMBINAISON DE GLYCOPYRROLATE (INCLUANT LES SELS ACCEPTABLES PHARMACEUTIQUEMENT, LES ESTERS, LES ENANTIOMERES OU LES AUTRES DERIVES DE CECI) ET DE FORMOTEROL (INCLUANT LES SELS ACCEPTABLES PHARMACEUTIQUEMENT, LES ESTERS, LES ENANTIOMERES OU LES AUTRES DERIVES DE CECI); AUTHORISATION NUMBER AND DATE: EU/1/18/1339 20181220
1267866 CR 2013 00015 Denmark   Start Trial PRODUCT NAME: GLYCOPYRRONIUM ELLER ET SALT DERAF, HERUNDER GLYCOPYRRONIUMBROMID; REG. NO/DATE: EU/1/12/788/001-006 20121003
1267866 2014C/022 Belgium   Start Trial DETAILS ASSIGNMENT: CHANGE OF OWNER(S), AUTRE, ADRESSE (NO SUPPRIME)
1267866 92166 Luxembourg   Start Trial PRODUCT NAME: GLYCOPYRRONIUM OU UN DE SES SELS
2435025 LUC00124 Luxembourg   Start Trial PRODUCT NAME: UNE COMBINAISON DE GLYCOPYRROLATE (Y COMPRIS SES SELS, ESTERS, ENANTIOMERES OU AUTRES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES) ET DE FORMOTEROL (Y COMPRIS SES SELS, ESTERS, ENANTIOMERES OU AUTRES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/18/1339 20181220
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Boehringer Ingelheim
Moodys
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.